$ARTL
ARTELO BIOSCIENCES, INC.

2024 Q4 Form 10-Q Financial Statement

#000164033424001677 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $870.0K $1.030M
YoY Change -15.53% -21.73%
% of Gross Profit
Research & Development $325.0K $1.585M
YoY Change -79.5% 47.03%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.195M $2.614M
YoY Change -54.28% 9.19%
Operating Profit -$1.195M -$2.614M
YoY Change -54.28% 9.19%
Interest Expense $63.00K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $63.00K $165.0K
YoY Change -61.82% 157.81%
Pretax Income -$1.132M -$2.450M
YoY Change -53.8% 5.15%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.132M -$2.449M
YoY Change -53.78% 5.11%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.35 -$0.83
COMMON SHARES
Basic Shares Outstanding 3.228M shares 3.228M shares 2.886M shares
Diluted Shares Outstanding 3.228M shares 2.949M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.857M $2.639M
YoY Change 84.05% -69.4%
Cash & Equivalents $4.357M $2.639M
Short-Term Investments $500.0K $0.00
Other Short-Term Assets $129.0K $560.0K
YoY Change -76.96% -31.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.986M $13.43M
YoY Change -62.87% -33.86%
LONG-TERM ASSETS
Property, Plant & Equipment $108.0K $30.00K
YoY Change 260.0% -57.14%
Goodwill
YoY Change
Intangibles $2.039M $2.039M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $3.000K $0.00
YoY Change -100.0%
Total Long-Term Assets $2.150M $2.071M
YoY Change 3.81% -1.94%
TOTAL ASSETS
Total Short-Term Assets $4.986M $13.43M
Total Long-Term Assets $2.150M $2.071M
Total Assets $7.136M $15.50M
YoY Change -53.96% -30.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $627.0K $840.0K
YoY Change -25.36% 104.38%
Accrued Expenses $34.00K $30.00K
YoY Change 13.33% -28.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $697.0K $921.0K
YoY Change -24.32% 91.88%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $78.00K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $78.00K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $697.0K $921.0K
Total Long-Term Liabilities $78.00K $0.00
Total Liabilities $775.0K $921.0K
YoY Change -15.85% 79.88%
SHAREHOLDERS EQUITY
Retained Earnings -$46.36M -$37.24M
YoY Change 24.49% 34.52%
Common Stock $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.361M $14.58M
YoY Change
Total Liabilities & Shareholders Equity $7.136M $15.50M
YoY Change -53.96% -30.85%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.132M -$2.449M
YoY Change -53.78% 5.11%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$778.0K -$1.800M
YoY Change -56.78% 6.13%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $4.250M -$1.830M
YoY Change -332.24% -40.58%
Cash From Investing Activities $4.250M -$1.830M
YoY Change -332.24% -40.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 540.0K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -778.0K -1.800M
Cash From Investing Activities 4.250M -1.830M
Cash From Financing Activities 0.000 540.0K
Net Change In Cash 3.472M -3.090M
YoY Change -212.36% -35.3%
FREE CASH FLOW
Cash From Operating Activities -$778.0K -$1.800M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2449000 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3227700 shares
us-gaap Net Income Loss
NetIncomeLoss
-6048000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
18262000 usd
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
20000000 usd
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
372012 shares
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
622000 usd
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
38741 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
55000 usd
artl Aggregate Value For Registration
AggregateValueForRegistration
75000000 usd
us-gaap Proceeds From Sale Of Federal Reserve Stock
ProceedsFromSaleOfFederalReserveStock
75000000 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
75000000 usd
us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1349000 usd
us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1206000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4357000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2815000 usd
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
500000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7611000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
903002 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
772424 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
38741 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
55000 usd
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3227700 shares
CY2024Q3 artl Intrinsic Value Of The Warrants
IntrinsicValueOfTheWarrants
0 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039000 usd
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On April 19, 2022, the Company entered into a 2nd lease arrangement for office space with an annual rent of $13 (£11) with the term of April 2022 through September 2023.
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
500000 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
7611000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
306666 shares
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
535000 usd
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3188959 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001621221
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
416667 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3227700 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38951
dei Entity Registrant Name
EntityRegistrantName
ARTELO BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-1220924
dei Entity Address Address Line1
EntityAddressAddressLine1
505 Lomas Santa Fe
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 160
dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Country
EntityAddressCountry
US
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
925-7049
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ARTL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3227700 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4357000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2815000 usd
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
500000 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
7611000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
129000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
554000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
4986000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
10980000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
108000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21000 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2039000 usd
CY2024Q3 us-gaap Other Assets
OtherAssets
3000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
3000 usd
CY2024Q3 us-gaap Assets
Assets
7136000 usd
CY2023Q4 us-gaap Assets
Assets
13043000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
627000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1238000 usd
CY2024Q3 artl Due To Related Parties
DueToRelatedParties
36000 usd
CY2023Q4 artl Due To Related Parties
DueToRelatedParties
30000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
34000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
697000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1291000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
78000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2024Q3 us-gaap Liabilities
Liabilities
775000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1291000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3188959 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52934000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52262000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46358000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40310000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-218000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-203000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6361000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11752000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7136000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13043000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
870000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1029000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2779000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3118000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
325000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1585000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3517000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3572000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1195000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2614000 usd
us-gaap Operating Expenses
OperatingExpenses
6296000 usd
us-gaap Operating Expenses
OperatingExpenses
6690000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1195000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2614000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6296000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6690000 usd
CY2024Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
63000 usd
CY2023Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
165000 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
248000 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
474000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
63000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
165000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
248000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
474000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1132000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2449000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6048000 usd
us-gaap Net Income Loss
NetIncomeLoss
-6216000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
55000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-15000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-15000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
55000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1147000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2447000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6063000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6161000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.15
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3228000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2949000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3213000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2887000 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11752000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
55000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
213000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2483000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9537000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
195000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2433000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
7299000 usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
209000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1132000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-15000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
6361000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19403000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
354000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2168000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
49000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
17638000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
225000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1599000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
16268000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
535000 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
222000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
14578000 usd
us-gaap Profit Loss
ProfitLoss
6048000 usd
us-gaap Profit Loss
ProfitLoss
6216000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
617000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
801000 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
248000 usd
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
474000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
24000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
30000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-518000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-357000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-629000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-72000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
5000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-5000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-22000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-32000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5783000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5611000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
481000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12736000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
7750000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
11990000 usd
artl Proceeds From Disposition Of Available For Sale Securities
ProceedsFromDispositionOfAvailableForSaleSecurities
0 usd
artl Proceeds From Disposition Of Available For Sale Securities
ProceedsFromDispositionOfAvailableForSaleSecurities
1512000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7269000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
766000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
55000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
535000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
535000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1542000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4249000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2815000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6888000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4357000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2639000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
artl Non Cash Transaction Initial Recognition Of The Right Of Use Asset And Lease Liability
NonCashTransactionInitialRecognitionOfTheRightOfUseAssetAndLeaseLiability
111000 usd
artl Non Cash Transaction Initial Recognition Of The Right Of Use Asset And Lease Liability
NonCashTransactionInitialRecognitionOfTheRightOfUseAssetAndLeaseLiability
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ARTELO BIOSCIENCES, INC. (“we”, “us”, “our”, the “Company”) is a Nevada corporation incorporated on May 2, 2011, and based in San Diego County, California. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America (“GAAP”), and the Company’s fiscal year end is December 31.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company registered wholly owned subsidiaries in Ireland, Trinity Reliant Ventures Limited, on November 11, 2016, and in the UK, Trinity Research &amp; Development Limited, on June 2, 2017. On January 8, 2020, Trinity Research and Development Limited changed its name to Artelo Biosciences Limited. The Company incorporated a wholly owned subsidiary in Canada, Artelo Biosciences Corporation, on March 18, 2020. Operations in the subsidiaries have been consolidated in the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics that target lipid-signaling pathways, including treatments intended to modulate the endocannabinoid system (the “ECS”), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Liquidity</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred losses since inception and incurred a net loss of $6,048 during the nine months ended September 30, 2024. However, in November 2021, the Company completed an equity offering which generated net proceeds of $18,262. Additionally, in May 2022, the Company entered into a purchase agreement and a registration rights agreement (the “Equity Line”) with an institutional investor, providing for the sale of up to $20,000 worth of the Company’s Common Stock, over the thirty-six (36) month term of the purchase agreement. Under the terms and subject to the conditions of the purchase agreement, the Company has the right, but not the obligation, to sell to the institutional investor, and the institutional investor is obligated to purchase, up to $20,000 worth of shares of the Company’s Common Stock. As of September 30, 2024, in accordance with the Equity Line, the Company issued 372,012 shares of the Company’s Common Stock with aggregate proceeds to the Company of $622, of which 38,741 shares were issued for proceeds to the Company of $55 during the nine months ended September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In July 2023, the Company filed a $75,000 in aggregate value shelf registration statement on Form S-3 which became effective on July 14, 2023. The shelf registration statement is effective for three years and permits the Company to sell, from time to time, up to $75,000 of the Company’s Common Stock, preferred stock, debt securities, warrants, and/or units subject to a limit of one-third (1/3) of the Company’s public float within a twelve (12) month period if the public float of the Company is less than $75,000. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s existing cash resources are expected to provide sufficient funds to carry out the Company’s planned operations into the fourth quarter of 2025.  To continue operations beyond such time frame, the Company will be required to raise additional funds by completing additional equity or debt offerings or licensing our product candidates. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Negative Global or National Events</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Businesses have been and will continue to be impacted by a number of challenging global and national events and circumstances that continue to evolve, including pandemics, extreme weather conditions, increased economic uncertainty, inflation, rising interest rates, recent and any potential future financial institution failures, and conflicts in Eastern Europe, the Middle East and in other countries. The extent of the impact of these events and circumstances on our business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and scope of the events and their impact on our development activities, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. We have been and continue to actively monitor the potential impacts that these various events and circumstances may have on our business, and we take steps, where warranted, to minimize any potential negative impacts on our business resulting from these events and circumstances. The ultimate impact of these global and national events and circumstances, either individually or in aggregate, is highly uncertain and subject to change.</p>
CY2022Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
20000000 usd

Files In Submission

Name View Source Status
0001640334-24-001677-index-headers.html Edgar Link pending
0001640334-24-001677-index.html Edgar Link pending
0001640334-24-001677.txt Edgar Link pending
0001640334-24-001677-xbrl.zip Edgar Link pending
artl-20240930.xsd Edgar Link pending
artl_10q.htm Edgar Link pending
artl_ex311.htm Edgar Link pending
artl_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
artl-20240930_cal.xml Edgar Link unprocessable
artl-20240930_def.xml Edgar Link unprocessable
artl-20240930_lab.xml Edgar Link unprocessable
artl-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
artl_10q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending